ADC (Antibody Drug Conjugates)

I-Antibody-drug conjugates (ADCs) zijolise kunyango lwe-immunotherapies olusebenzisa amachiza anamandla e-cytotoxic adityaniswe kwizilwa-buhlungu ngokudibanisa imichiza. Oku kwandisa ukusebenza kwe-chemotherapeutic agents ngokujolisa ngokufanelekileyo ichiza ngokuthe ngqo kwiiseli zomhlaza. Ngoko ke, ii-ADCs nazo ziye zanciphisa iziphumo ebezingalindelekanga kuba ukujolisa kwiiseli zomhlaza kuthetha ukuba ngaphantsi kwechiza le-cytotoxic liya kungena kwiiseli eziphilileyo.

Iqonga leteknoloji ye-ADC yesizukulwana esilandelayo se-Sorrento isebenzisa iindlela ezintsha zokudibanisa ukuvelisa ii-ADC ezizinzileyo ngokudibanisa i-toxin kwiindawo ezithile kuphela, ezikhethwe kwangaphambili ze-antibody; iziphumo ze-ADCs zibonise ukusebenza kakuhle kwe-anti-tumor kwizifundo zangaphambili.

Itekhnoloji ye-ADC isebenzisa iikhemistri zokudibanisa (i-C-Lock™ kunye ne-K-Lock™), eyaqala yaphuhliswa yi-Concortis Biosystems, Corp.

Indibaniselwano ye-C-Lock kunye ne-K-Lock yokudibanisa iindlela zenza ii-ADCs ezisebenza ngeendlela ezininzi, ezifana ne-ADCs yamachiza amabini kunye ne-Bispecific ADCs. Sikwafunda ngenkuthalo indibaniselwano yee-ADCs kunye nonyango lwe-immuno-oncology njengesicwangciso esitsha sokulwa nomhlaza.

Siphuhlisa ii-ADCs ezijolise kwi-CD38 kunye ne-BCMA.